ProfileGDS5678 / 1416122_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 78% 78% 88% 80% 77% 79% 86% 88% 77% 71% 79% 77% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3876878
GSM967853U87-EV human glioblastoma xenograft - Control 25.3605178
GSM967854U87-EV human glioblastoma xenograft - Control 35.4037378
GSM967855U87-EV human glioblastoma xenograft - Control 47.0841588
GSM967856U87-EV human glioblastoma xenograft - Control 55.6968880
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0393177
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4173679
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4355986
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7850688
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3129177
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4109671
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5505479
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2580677
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1683677